{
    "organizations": [],
    "uuid": "43cc477e25d417b7e92b2614bb471d30c89b0dd2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-oncology-venture-announces-positiv/brief-oncology-venture-announces-positive-interim-results-from-a-phase-1-2-study-idUSFWN1PQ0G3",
    "ord_in_thread": 0,
    "title": "BRIEF-Oncology Venture Announces Positive Interim Results From A Phase 1/2 Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 31 (Reuters) - ONCOLOGY VENTURE SWEDEN AB:\n* ANNOUNCES POSITIVE INTERIM RESULTS FROM A PHASE 1/2 STUDY WITH LIPLACIS AND ITS DRP IN HEAVILY PRETREATED METASTATIC BREAST CANCER PATIENTS\n* STUDY IS PROGRESSING ACCORDING TO PLAN, AND LAST PATIENT IS EXPECTED TO BE INCLUDED BEFORE END OF Q1 2018.\n* ‍LAST PATIENT IS EXPECTED TO BE INCLUDED BEFORE END OF Q1 2018.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-31T16:34:00.000+02:00",
    "crawled": "2018-02-01T15:48:40.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "oncology",
        "venture",
        "sweden",
        "ab",
        "announces",
        "positive",
        "interim",
        "result",
        "phase",
        "study",
        "liplacis",
        "drp",
        "heavily",
        "pretreated",
        "metastatic",
        "breast",
        "cancer",
        "patient",
        "study",
        "progressing",
        "according",
        "plan",
        "last",
        "patient",
        "expected",
        "included",
        "end",
        "q1",
        "patient",
        "expected",
        "included",
        "end",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}